Royalty Pharma plc

RPRX

GB00BMVP7Y09

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
44.65 ^USD	+1.25%		+7.13%	+15.55%

01-30	Sector Update: Health Care Stocks Higher Late Afternoon	MT
01-30	Sector Update: Health Care	MT

Royalty Pharma acquires remaining royalty interest in Roche's Evrysdi for $240 million

Published on 12/29/2025 at 10:48 pm GMT

Reuters

Latest news about Royalty Pharma plc

01-30	Sector Update: Health Care Stocks Higher Late Afternoon	MT
01-30	Sector Update: Health Care	MT
01-30	Royalty Pharma Shares Rise After UBS Upgrade	MT
01-30	UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38	MT
01-30	The Fed's Next Chair: Reformist, Realist, or Rubber Stamp?
01-30	Analyst recommendations: Arista Networks, Dow, SouthWest Airlines, Coreweave, Meta Platforms…
01-20	Royalty Pharma to announce fourth quarter and full year 2025 financial results on February 11, 2026	RE
01-13	Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing	MT
01-13	Royalty Pharma plc Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 09:45 AM
01-12	Teva's US Affiliate, Royalty Pharma Sign $500 Million Financing Deal for Potential Vitiligo Treatment	MT
01-11	Teva and Royalty Pharma enter agreement to accelerate development of potential treatment for vitiligo	RE
01-09	Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026	CI
01-09	Royalty Pharma announces dividend increase	RE
01-09	Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20.	MT
12-29	Royalty Pharma acquires remaining royalty interest in Roche's Evrysdi for $240 million	RE
12-29	Royalty Pharma Buys Remaining Royalty Interest in Roche's Evrysdi	MT
12-22	Royalty Pharma plc Announces Executive Changes	CI
12-17	Royalty Pharma Insider Sold Shares Worth $766,420, According to a Recent SEC Filing	MT
12-16	Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies	MT
12-16	Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million	RE
12-05	Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing	MT
12-04	Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement	RE
12-04	Royalty Pharma, Denali Sign $275 Million Hunter Syndrome Treatment Royalty Deal	MT
12-03	Royalty Pharma plc Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 03:50 PM
12-02	Royalty Pharma plc Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 03:15 PM

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertexâ€™s Trikafta, GSKâ€™s Trelegy, Rocheâ€™s Evrysdi, Johnson & Johnsonâ€™s Tremfya, Biogenâ€™s Tysabri and Spinraza, AbbVie and Johnson & Johnsonâ€™s Imbruvica, Astellas and Pfizerâ€™s Xtandi, Novartisâ€™ Promacta, Pfizerâ€™s Nurtec ODT and Gileadâ€™s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.

Employees

Sector

Pharmaceuticals

Calendar

02-10 - Q4 2025 Earnings Release

More about the company